Premier Alternatives

STORM Therapeutics

Cambridge, United Kingdom · Founded 2015 · Privately Held (backing)

Operator of a biotechnology and drug discovery company intended to develop small molecule therapies for RNA modification enzymes for use in the treatment of cancer and other immune diseases. STORM Therapeutics is based in Cambridge, United Kingdom and was founded in 2015. Its last reported valuation was $90.3 million in Dec 2022. It has raised $172 million.

Last reported valuation
$90.3M
Oct 2026
Priced at
—
Total raised
$172.2M
Last round
—

STORM Therapeutics key facts

as of Oct 2026
  • Operator of a biotechnology and drug discovery company intended to develop small molecule therapies for RNA modification enzymes for use in the treatment of cancer and other immune diseases.
  • STORM Therapeutics is valued at approximately $90.3M as of Oct 2026 (last reported valuation).
  • It has raised $172.2M; the latest was Later Stage VC ($56.0M) in Apr 2026.
  • Notable investors include Innovate UK, Cambridge Enterprise Ventures, M Ventures, UTokyo Innovation Platform Company, Pfizer Ventures — 12 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$90.3M

STORM Therapeutics's last reported valuation, Dec 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of STORM Therapeutics with a free account
  • ·The complete investor list: 12 names
  • ·Watch STORM Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

STORM Therapeutics funding rounds

No rounds on record

No funding rounds for STORM Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

STORM Therapeutics valuation

STORM Therapeutics's last reported valuation was $90.3 million in Dec 2022. No priced round, secondary trade or fund mark has surfaced since.

STORM Therapeutics investors

12 investors are on record for STORM Therapeutics, including Innovate UK, Cambridge Enterprise Ventures, M Ventures and UTokyo Innovation Platform Company.

About STORM Therapeutics

Operator of a biotechnology and drug discovery company intended to develop small molecule therapies for RNA modification enzymes for use in the treatment of cancer and other immune diseases. The company's drug discovery and RNA analytics platform tackles diseases through modulating RNA-modifying enzymes and identifies novel targets and first-in-class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases, providing physicians with first-in-class therapies against RNA epigenetic targets.

Sector
Healthcare
HQ
Cambridge, United Kingdom
Founded
2015
Employees
33
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.